Why the study?
Enhanced recovery after surgery reduces complications and hospital stay, but its role in living donor nephrectomy has not yet been defined.
Does enhanced recovery after surgery (ERAS) reduce hospital stay and opiate requirements in patients undergoing living donor nephrectomy?
Does enhanced recovery after surgery (ERAS) reduce hospital stay and opiate requirements in patients undergoing living donor nephrectomy?
ERAS protocols in laparoscopic living donor nephrectomy significantly reduce hospital length of stay and opiate requirements without increasing readmissions or complications.
ERAS may be adopted for living donor nephrectomy to reduce complications and stay; extends ERAS benefits to this donor population.
Enhanced recovery after surgery (ERAS) reduces complications and shortens hospital stay without increasing readmission or mortality. However, its role in living donor nephrectomy (LDN) has not yet been defined. Medline, Embase, CINAHL, PsycINFO, and Cochrane Central were searched prior to 08/01/21 for all randomized controlled and cohort studies comparing ERAS to standard of care in LDN. The study was registered on PROSPERO (CRD: CRD42019141706). One thousand, three hundred seventy-seven patients were identified from 14 studies (698 patients with ERAS and 679 patients without). There were considerable differences in the protocols used, and compliance with general ERAS recommendations was poor. Meta-analysis of laparoscopic procedures (including hand- and robot-assisted) revealed that duration of stay was significantly reduced by 0.98 days with ERAS (95% CI = 0.36-1.60, P = .002) and opiate requirement by 32.4 mg (95% CI = 1.1-63.7, P = .04). There was no significant difference n readmission rates or complications. Quality of evidence was low to moderate assessed using the GRADE tool. This review suggests there is a positive benefit of ERAS in laparoscopic LDN. However, there was considerable variation in ERAS protocols used, and the quality of evidence was low; as such, a guideline for ERAS in LDN should be developed and validated.
No takes yet. Share an insight, caveat, or question.
Byrne et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: